A clinical trial on Veppampisin chooranam in the management of Madhumegam (Type II Diabetes Mellitus)

A PROSPECTIVE, OPEN LABELLED, SINGLE ARM, NON-RANDOMIZED, SINGLE CENTRIC, PHASE II, CLINICAL TRIAL TO DETERMINE THE EFFECTIVENESS OF VEPPAMPISIN CHOORANAM IN THE MANAGEMENT OF MADHUMEGAM (TYPE II DIABETES MELLITUS) - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105889

Enrollment

Registered

2026-03-11

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Veppampisin chooranam: Dosage:1 gram, Twice a day for 90days Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: If patient is having anyone among the three(WHO Criteria 2019) FBS-Above 126mg/dl and below 250mg/dl or PPBS-Above 200mg/dl and below 350mg/dl or HbA1c-6.5% to 10% Patients with symptoms of polyuria, polydipsia, polyphagia and nocturia

Exclusion criteria

Exclusion criteria: Type 1 Diabetes Mellitus Gestational DM Diabetes Insipidus Pregnancy Lactating mother Chronic kidney disease Chronic liver disease Ischaemic heart disease

Design outcomes

Primary

Measure	Time frame
If during treatment or after treatment FBS became below 126mg/dl & PPBS below 200mg/dl and HbA1c below 6.5%Timepoint: 90 days	—

Secondary

Measure	Time frame
Reduction of the sign and symptoms of polyuria, polydipsia, polyphagia and nocturiaTimepoint: 6 months	—

Countries

India

Contacts

Public ContactDR S JUSTUS ANTONY

Government Siddha Medical College and Hospital, Palayamkottai.

drpsk_md@yahoo.in9944337757

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026